Prognosis of advanced hepatocellular carcinoma: a new stratification of Barcelona Clinic Liver Cancer stage C: results from a French multicenter study
| Autor: | Adhoute, Xavier, Penaranda, Guillaume, Raoul, Jean L., Blanc, Jean F., Edeline, Julien, Conroy, Guillaume, Perrier, Herve, Pol, Bernard, Bayle, Olivier, Monnet, Olivier, Beaurain, Patrick, Muller, Cyril, Castellani, Paul, Bronowicki, Jean-Pierre, Bourlière, Marc |
|---|---|
| Přispěvatelé: | Hôpital Saint-Joseph [Marseille], Alphabio Laboratory, Hôpital Européen [Fondation Ambroise Paré - Marseille], Foie, métabolismes et cancer, Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Département d'oncologie médicale [Rennes], CRLCC Eugène Marquis (CRLCC), Service d'Hépato-gastro-entérologie [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Nutrition-Génétique et Exposition aux Risques Environnementaux (NGERE), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL), Service d'hépato-gastro-entérologie, Assistance Publique - Hôpitaux de Marseille (APHM), Bayer, Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ) |
| Rok vydání: | 2015 |
| Předmět: |
Male
Niacinamide Carcinoma Hepatocellular Survival [SDV]Life Sciences [q-bio] Angiogenesis Inhibitors transarterial chemoembolization Kaplan-Meier Estimate system Risk Assessment vein tumor thrombus Decision Support Techniques infiltrative tumor alpha-fetoprotein Predictive Value of Tests Risk Factors Validation Hepatectomy Humans Aged Neoplasm Staging Proportional Hazards Models Retrospective Studies Chi-Square Distribution Phenylurea Compounds Liver Neoplasms trials Reproducibility of Results Barcelona Clinic Liver Cancer stage Middle Aged Sorafenib digestive system diseases Treatment Outcome classification ROC Curve Area Under Curve Multivariate Analysis Female France Liver cancer management Algorithms |
| Zdroj: | European Journal of Gastroenterology & Hepatology European Journal of Gastroenterology & Hepatology, 2016, 28 (4), pp.433--440. ⟨10.1097/MEG.0000000000000558⟩ European Journal of Gastroenterology and Hepatology European Journal of Gastroenterology and Hepatology, Lippincott, Williams & Wilkins, 2016, 28 (4), pp.433--440. ⟨10.1097/MEG.0000000000000558⟩ |
| ISSN: | 1473-5687 0954-691X |
| Popis: | International audience; Background Advanced hepatocellular carcinoma (HCC) includes a wide spectrum of tumors and patients' prognosis after treatment is highly variable. Moreover, therapeutic options based on the Barcelona Clinic Liver Cancer (BCLC) staging system algorithm are restricted to one systemic therapy. Aim of the study To refine the stratification among BCLC C HCC patients by establishing a new simple prognostic score. Patients and methods A regression model based on a BCLC stage C population and validated with an external cohort of BCLC C HCC patients defined the score. It was therefore validated among three external cohorts of BCLC C HCC patients treated with sorafenib. Results Five variables had independent prognostic values: the number of nodules, the infiltrating nature of the HCC, alpha-fetoprotein serum level, Child-Pugh score, and Eastern Cooperative Oncology Group Performance Status grade. They were integrated into a new score named NIACE ranging from 0 to 7, well correlated with survival. With the use of one threshold value, this score enables defining of two populations with different survivals among BCLC C patients and specifically among those treated with sorafenib. Conclusion The NIACE score defines different prognostic subgroups after palliative treatment of HCC. It could be an additional tool for BCLC C HCC before inclusion in clinical trials or for the management of patients. These results must be validated in a prospective study |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|